Paper35637990
Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.
Dar S and 7 others. Ann Med Surg (Lond), 2022. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. Papers, record 35637990. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35637990
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3802833 | Meta-analysis in clinical trials. | Control Clin Trials | 1986 | https://conductscience.org/library/papers/3802833 | PubMed |
| 2 | 29286050 | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. | Nat Rev Endocrinol | 2018 | https://conductscience.org/library/papers/29286050 | PubMed |
| 3 | 28086872 | Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. | Cardiovasc Diabetol | 2017 | https://conductscience.org/library/papers/28086872 | PubMed |
| 4 | 28683796 | Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. | Cardiovasc Diabetol | 2017 | https://conductscience.org/library/papers/28683796 | PubMed |
| 5 | 28930295 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. | Nat Rev Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/28930295 | PubMed |
| 6 | 25865049 | Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25865049 | PubMed |
| 7 | 33520110 | Novel glucose-lowering drugs for non-alcoholic fatty liver disease. | World J Diabetes | 2021 | https://conductscience.org/library/papers/33520110 | PubMed |
| 8 | 34507895 | The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. | Dig Liver Dis | 2022 | https://conductscience.org/library/papers/34507895 | PubMed |
| 9 | 34446261 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | Rev Esp Cardiol (Engl Ed) | 2021 | https://conductscience.org/library/papers/34446261 | PubMed |
| 10 | 32152903 | Epidemiology of non-alcoholic fatty liver disease in Asia. | Indian J Gastroenterol | 2020 | https://conductscience.org/library/papers/32152903 | PubMed |
| 11 | 33035599 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. | Diabetes Res Clin Pract | 2020 | https://conductscience.org/library/papers/33035599 | PubMed |
| 12 | 33789826 | The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. | Int J Surg | 2021 | https://conductscience.org/library/papers/33789826 | PubMed |
| 13 | 32083798 | Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. | J Diabetes Investig | 2020 | https://conductscience.org/library/papers/32083798 | PubMed |
| 14 | 30414863 | Non-alcoholic fatty liver disease - A global public health perspective. | J Hepatol | 2019 | https://conductscience.org/library/papers/30414863 | PubMed |
| 15 | 17130197 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Diabetes Care | 2006 | https://conductscience.org/library/papers/17130197 | PubMed |
| 16 | 24402015 | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. | Arq Bras Endocrinol Metabol | 2013 | https://conductscience.org/library/papers/24402015 | PubMed |
| 17 | 25554560 | Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. | Clin Ther | 2015 | https://conductscience.org/library/papers/25554560 | PubMed |
| 18 | 32314464 | Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB). | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/32314464 | PubMed |
| 19 | 17157112 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Clin Ther | 2006 | https://conductscience.org/library/papers/17157112 | PubMed |
| 20 | 33396949 | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | Metabolites | 2020 | https://conductscience.org/library/papers/33396949 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42878985 | GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases. | Curr Atheroscler Rep | 2026 | https://conductscience.org/library/papers/42878985 | PubMed |
| 42794744 | Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794744 | PubMed |
| 41143728 | Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus. | Eur Heart J Cardiovasc Pharmacother | 2025 | https://conductscience.org/library/papers/41143728 | PubMed |
| 40823521 | Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial. | J Taibah Univ Med Sci | 2025 | https://conductscience.org/library/papers/40823521 | PubMed |
| 40652242 | Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. | Cardiovasc Diabetol | 2025 | https://conductscience.org/library/papers/40652242 | PubMed |
| 40309616 | Patient Adherence for Oral Combination Therapies in Diabetes Management: A Scoping Review. | Health Sci Rep | 2025 | https://conductscience.org/library/papers/40309616 | PubMed |
| 39525721 | Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39525721 | PubMed |
| 39396983 | Association of plasma arachidonic acid levels with a bipolar disorder and the effects of a FADS gene variant. | Transl Psychiatry | 2024 | https://conductscience.org/library/papers/39396983 | PubMed |
| 39386037 | Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China. | Diabetes Metab Syndr Obes | 2024 | https://conductscience.org/library/papers/39386037 | PubMed |
| 39201071 | Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients. | J Clin Med | 2024 | https://conductscience.org/library/papers/39201071 | PubMed |
| 38794138 | Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38794138 | PubMed |
| 38148417 | Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. | Curr Atheroscler Rep | 2024 | https://conductscience.org/library/papers/38148417 | PubMed |
| 37635974 | Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37635974 | PubMed |
| 37373310 | Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37373310 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DPP4 | 1803 | PubTator's text mining | https://conductscience.org/library/genes/1803 | NCBI Gene |
| EHMT1 | 79813 | PubTator's text mining | https://conductscience.org/library/genes/79813 | NCBI Gene |
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35637990
GET https://conductscience.org/api/papers/v1/35637990/references?page=2